Showing 161-170 of 216 results for "".
Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage IIB/IIC Melanoma
https://practicaldermatology.com/programs/cme/efficacy-and-safety-outcomes-for-adjuvant-immunotherapy-driving-guideline-recommendations-for-stage-iibiic-melanoma/36324/Explore guideline-based treatment strategies and clinical data to optimize guideline-concordant care for patients with melanoma in the neoadjuvant, adjuvant, and metastatic settings.Emerging and Practice Changing Data in Immunotherapy Strategies for Melanoma
https://practicaldermatology.com/programs/cme/emerging-and-practice-changing-data-in-immunotherapy-strategies-for-melanoma/36330/Explore guideline-based treatment strategies and clinical data to optimize guideline-concordant care for patients with melanoma in the neoadjuvant, adjuvant, and metastatic settings.Diversity in the Dermatology Workforce: What Can We Do?
https://practicaldermatology.com/topics/practice-management/diversity-in-the-dermatology-workforce-what-can-we-do/23057/Medicine in general lacks workforce diversity. Dermatology fares worse than other specialties. Here’s a closer look at the problem.Proton Pump Inhibitor-induced Dermal Hypersensitivity Reaction Masquerading as an Arthropod-bite Reaction
https://practicaldermatology.com/youngmd-connect/resident-resource-center/proton-pump-inhibitor-induced-dermal-hypersensitivity-reaction-masquerading-as-an-arthropod-bite-reaction/23940/Insights From Global Key Opinion Leaders on Regional Regulatory and Guideline Nuances to Optimize Melanoma Management
https://practicaldermatology.com/programs/cme/insights-from-global-key-opinion-leaders-on-regional-regulatory-and-guideline-nuances-to-optimize-melanoma-management/36331/Explore guideline-based treatment strategies and clinical data to optimize guideline-concordant care for patients with melanoma in the neoadjuvant, adjuvant, and metastatic settings.Physician Spotlight: Anne Chapas, MD
https://practicaldermatology.com/columns/physician-spotlight/physician-spotlight-anne-chapas-md/23390/Biologics for Psoriasis: A Status Update
https://practicaldermatology.com/topics/psoriasis/biologics-for-psoriasis-a-status-update/23006/The field has grown substantially from the early 2000s to include now a dozen innovator systemic agents, a host of biosimilars, and soon JAK Inhibitors.Complications of Biologic Therapy for Psoriasis: Part II
https://practicaldermatology.com/topics/psoriasis/complications-of-biologic-therapy-for-psoriasis-part-ii/22039/Therapeutic success requires clinicians to understand emerging and established safety concerns.Implementing Guideline-Concordant Care for a Patient With Newly Diagnosed BRAF-Mutant Stage IV Melanoma
https://practicaldermatology.com/programs/cme/implementing-guideline-concordant-care-for-a-patient-with-newly-diagnosed-braf-mutant-stage-iv-melanoma/36328/Explore guideline-based treatment strategies and clinical data to optimize guideline-concordant care for patients with melanoma in the neoadjuvant, adjuvant, and metastatic settings.Which Probiotic for Which Disease? Part 2
https://practicaldermatology.com/topics/atopic-dermatitis/which-probiotic-for-which-disease-part-2/23596/The conclusion of this 2-part series reviews the research for probiotics in the management of AD, acne, and psoriasis.